Noninfectious uveitis: strategies to optimize treatment compliance and adherence

被引：11

作者：

Dolz-Marco, Rosa ^{[1
]}

Gallego-Pinazo, Roberto ^{[1
]}

Diaz-Llopis, Manuel ^{[2
]}

Cunningham, Emmett T., Jr. ^{[3
,4
,5
,6
]}

Arevalo, J. Fernando ^{[7
,8
]}

机构：

[1] Univ & Polytech Hosp La Fe, Dept Ophthalmol, Unit Macula, Valencia, Spain

[2] Univ Valencia, Fac Med, E-46003 Valencia, Spain

[3] Calif Pacific Med Ctr, Dept Ophthalmol, San Francisco, CA USA

[4] Stanford Univ, Dept Ophthalmol, Sch Med, Stanford, CA 94305 USA

[5] Univ Calif San Francisco, Francis I Proctor Fdn, Med Ctr, San Francisco, CA 94143 USA

[6] West Coast Retina Med Grp, San Francisco, CA USA

[7] King Khalid Eye Specialist Hosp, Vitreoretina Div, Riyadh, Saudi Arabia

[8] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Retina Div, Baltimore, MD 21287 USA

来源：

CLINICAL OPHTHALMOLOGY | 2015年 / 9卷

关键词：

noninfectious uveitis; intraocular inflammation; immunosuppressive treatment; adherence; compliance; therapeutic failure;

D O I：

10.2147/OPTH.S36650

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

Noninfectious uveitis includes a heterogenous group of sight-threatening ocular and systemic disorders. Significant progress has been made in the treatment of noninfectious uveitis in recent years, particularly with regard to the effective use of corticosteroids and non-corticosteroid immunosuppressive drugs, including biologic agents. All of these therapeutic approaches are limited, however, by any given patient's ability to comply with and adhere to their prescribed treatment. In fact, compliance and adherence are among the most important patient-related determinants of treatment success. We discuss strategies to optimize compliance and adherence.

引用

页码：1477 / 1481

页数：5

共 50 条

[21] Adalimumab for the treatment of refractory noninfectious paediatric uveitis
Munoz-Gallego, Alicia
Barral, Estefania
Enriquez, Eugenia
Tejada, Pilar
Barcelo, Ana
de Inocencio, Jaime
[J]. INTERNATIONAL OPHTHALMOLOGY, 2017, 37 (03) : 719 - 725
[22] FK506 TREATMENT OF NONINFECTIOUS UVEITIS
ISHIOKA, M
OHNO, S
NAKAMURA, S
ISOBE, K
WATANABE, N
ISHIGATSUBO, Y
TANAKA, S
[J]. AMERICAN JOURNAL OF OPHTHALMOLOGY, 1994, 118 (06) : 723 - 729
[23] Strategies to optimize treatment adherence in adolescent patients with cystic fibrosis
Bishay, Lara C.
Sawicki, Gregory S.
[J]. ADOLESCENT HEALTH MEDICINE AND THERAPEUTICS, 2016, 7 : 117 - 124
[24] A systematic review of biologics for the treatment of noninfectious uveitis
Takeuchi, Masaru
[J]. IMMUNOTHERAPY, 2013, 5 (01) : 91 - 102
[25] Dexamethasone intravitreal implant for the treatment of noninfectious uveitis
Hunter, Rebecca S.
Lobo, Ann-Marie
[J]. CLINICAL OPHTHALMOLOGY, 2011, 5 : 1613 - 1621
[26] Targeting Interleukin-23 in the Treatment of Noninfectious Uveitis
Pepple, Kathryn L.
Lin, Phoebe
[J]. OPHTHALMOLOGY, 2018, 125 (12) : 1977 - 1983
[27] Nonsteroidal drugs for the treatment of noninfectious posterior and intermediate uveitis
Imrie, Fraser R.
Dick, Andrew D.
[J]. CURRENT OPINION IN OPHTHALMOLOGY, 2007, 18 (03) : 212 - 219
[28] Indications and effects of biological agents in the treatment of noninfectious uveitis
Li, Bowen
Yang, Li
Bai, Feng
Tong, Bainan
Liu, Xiaoli
[J]. IMMUNOTHERAPY, 2022, : 985 - 994
[29] Efficacy and Safety of Tacrolimus for the Treatment of Pediatric Noninfectious Uveitis
Pan, Ingrid
Lin, Clara
Palestine, Alan
Jung, Jennifer
[J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2022, 63 (07)
[30] Effect of dexamethasone intravitreal implant in the treatment of noninfectious uveitis
Frere, A.
Janssens, X.
Makhoul, D.
Judice, L.
Postelmans, L.
Lefebvre, P.
Caspers, L.
Willermain, F.
[J]. ACTA OPHTHALMOLOGICA, 2015, 93

← 1 2 3 4 5 →